Semaglutide

Drug Profile

Semaglutide

Alternative Names: NN-9535; NN-9536; NNC-0113-0217

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Novo Nordisk; Zosano Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 02 Apr 2017 Results from a post hoc analysis of the phase III SUSTAIN™ 2, 3 and 4 trials in Type-2 diabetes mellitus reported at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 15 Mar 2017 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in Russia, Japan, Canada, USA and Austria (SC) (NCT03086330)
  • 15 Mar 2017 Phase-III clinical trials in Type-2 diabetes mellitus in Austria (SC) (NCT03086330)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top